ROCO
6612
Market cap107mUSD
Oct 07, Last price
72.20TWD
1D
-0.55%
1Q
6.96%
Jan 2017
98.79%
IPO
102.92%
Name
Icares Medicus Inc
Chart & performance
P/E
1,113.35
P/S
3.02
EPS
0.06
Div yield, %
0.42%
Shrs. gr., 5y
3.03%
Rev. gr., 5y
25.54%
Revenues
1.13b
+31.54%
Net income
3m
-97.02%
CFO
-59m
L+443.54%
Dividend
Aug 26, 20260.3325 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ICARES Medicus, Inc. operates as a dedicated nano-medical materials company, engaging in the entire lifecycle from innovation and production to global distribution of advanced ophthalmic medical materials. Its core offerings encompass a range of ocular solutions, most notably intraocular lenses (IOLs) designed to correct visual impairments such as cataracts, nearsightedness (myopia), farsightedness (hyperopia), age-related vision loss (presbyopia), and astigmatism. Additionally, the company supplies sophisticated surgical implantation systems along with comprehensive technical support services. Established in 2011, ICARES Medicus, Inc. maintains its headquarters in Zhubei, Taiwan.
Key people
Tan-Li Chen
Group Chief Financial Officer, Head of Finance & Accounting, Corporate Governance Officer · since 2024
Bingchun Chen
General Manager · since 2024
Chun-Ming Lin
Deputy General Manager-Operation · since 2023
Robert Cummings
General Manager-Subsidiary · since 2015
William Lee
Vice Chairman of the Board · since 2024
Ih-Houng Loh
Chairman of the Board · since 2025
Wen-Chu Tseng
Director · since 2025
Ying-Zong Yan
Director · since 2016
Jhih-Ying Guo
Independent Director · since 2017
Zhiqiu Guo
Independent Director · since 2022
Kai-Yuan Tan
Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||